![]() |
Scientists at St. Jude collaborated to better understand CTCF. L to R: Beisi Xu, PhD, Chunliang Li, PhD; Judith Hyle; Mohamed Nadhir Djekidel, PhD. Photo Credit: St. Jude Children's Research Hospital |
Scientists at St. Jude Children’s Research Hospital used the auxin-inducible degron 2 system on CTCF, bringing the novel approach to bear on a fundamental protein.
CTCF is a critical protein known to play various roles in key biological processes such as transcription. Scientists at St. Jude Children’s Research Hospital used a next-generation protein degradation technology to study CTCF. Their work revealed the superiority of the approach in addition to providing functional insights into how CTCF regulates transcription. The study, published today in Genome Biology, paves the way for more clear, nuanced studies of CTCF.
Transcription is an essential biological process where DNA is copied into RNA. The process is the first required step in a cell to take the instructions housed in DNA and ultimately translate that code into the amino acid or polypeptide building blocks that become active proteins. Dysregulated transcription plays a role in many types of pediatric cancer. Finding ways to modify or target aspects of the transcriptional machinery is a novel frontier in the search for vulnerabilities that can be exploited therapeutically.
While the biology of CTCF has been extensively studied, how the different domains (parts) of CTCF function in relation to transcription regulation remains unclear.